480 related articles for article (PubMed ID: 35356532)
1. Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids.
Sun Q; Xin X; An Z; Hu Y; Feng Q
Front Cell Infect Microbiol; 2022; 12():854879. PubMed ID: 35356532
[TBL] [Abstract][Full Text] [Related]
2. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
[TBL] [Abstract][Full Text] [Related]
3. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites.
Ding Y; Yanagi K; Cheng C; Alaniz RC; Lee K; Jayaraman A
Pharmacol Res; 2019 Mar; 141():521-529. PubMed ID: 30660825
[TBL] [Abstract][Full Text] [Related]
4. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease.
Petrov PD; García-Mediavilla MV; Guzmán C; Porras D; Nistal E; Martínez-Flórez S; Castell JV; González-Gallego J; Sánchez-Campos S; Jover R
Mol Nutr Food Res; 2019 Oct; 63(20):e1900487. PubMed ID: 31322321
[TBL] [Abstract][Full Text] [Related]
5. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
Ni Y; Ni L; Zhuge F; Fu Z
Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
[TBL] [Abstract][Full Text] [Related]
6. Physical exercise plays a role in rebalancing the bile acids of enterohepatic axis in non-alcoholic fatty liver disease.
Zhang M; Xiao B; Chen X; Ou B; Wang S
Acta Physiol (Oxf); 2024 Jan; 240(1):e14065. PubMed ID: 38037846
[TBL] [Abstract][Full Text] [Related]
7. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
[TBL] [Abstract][Full Text] [Related]
8. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
Ji Y; Yin Y; Li Z; Zhang W
Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
[TBL] [Abstract][Full Text] [Related]
9. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism.
Liu J; Sun J; Yu J; Chen H; Zhang D; Zhang T; Ma Y; Zou C; Zhang Z; Ma L; Yu X
NPJ Biofilms Microbiomes; 2023 May; 9(1):29. PubMed ID: 37258543
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota-Related Cellular and Molecular Mechanisms in the Progression of Nonalcoholic Fatty Liver Disease.
Park E; Jeong JJ; Won SM; Sharma SP; Gebru YA; Ganesan R; Gupta H; Suk KT; Kim DJ
Cells; 2021 Oct; 10(10):. PubMed ID: 34685614
[TBL] [Abstract][Full Text] [Related]
12. The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease.
Ni Y; Lu M; Xu Y; Wang Q; Gu X; Li Y; Zhuang T; Xia C; Zhang T; Gou XJ; Zhou M
Front Microbiol; 2022; 13():908011. PubMed ID: 35832821
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Han R; Ma J; Li H
Front Med; 2018 Dec; 12(6):645-657. PubMed ID: 30178233
[TBL] [Abstract][Full Text] [Related]
14. Gut Microbiota and Plasma Bile Acids Associated with Non-Alcoholic Fatty Liver Disease Resolution in Bariatric Surgery Patients.
Pérez-Rubio Á; Soluyanova P; Moro E; Quintás G; Rienda I; Periañez MD; Painel A; Vizuete J; Pérez-Rojas J; Castell JV; Trullenque-Juan R; Pareja E; Jover R
Nutrients; 2023 Jul; 15(14):. PubMed ID: 37513605
[TBL] [Abstract][Full Text] [Related]
15. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
16. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.
Luo L; Chang Y; Sheng L
Life Sci; 2023 May; 321():121614. PubMed ID: 36965522
[TBL] [Abstract][Full Text] [Related]
17. Role of gut microbial metabolites in nonalcoholic fatty liver disease.
Zhao ZH; Lai JK; Qiao L; Fan JG
J Dig Dis; 2019 Apr; 20(4):181-188. PubMed ID: 30706694
[TBL] [Abstract][Full Text] [Related]
18. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
[TBL] [Abstract][Full Text] [Related]
19. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease.
Adams LA; Wang Z; Liddle C; Melton PE; Ariff A; Chandraratna H; Tan J; Ching H; Coulter S; de Boer B; Christophersen CT; O'Sullivan TA; Morrison M; Jeffrey GP
Liver Int; 2020 Jun; 40(6):1356-1365. PubMed ID: 32243703
[TBL] [Abstract][Full Text] [Related]
20. Disease-Associated Gut Microbiota Reduces the Profile of Secondary Bile Acids in Pediatric Nonalcoholic Fatty Liver Disease.
Yu J; Zhang H; Chen L; Ruan Y; Chen Y; Liu Q
Front Cell Infect Microbiol; 2021; 11():698852. PubMed ID: 34568090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
